相关实验视频

Updated: Jan 7, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

使用Ondansetron的主要心脏不良事件:系统性审查

Michael Cristian Garcia^1,2, Bhavya Gandhi¹, Faisal Quadri¹

¹Clinical Pharmacology & Toxicology Research Group, Research Institute of St Joe's Hamilton, Hamilton, Canada.

Clinical pharmacology and therapeutics

|December 31, 2025

概括

尽管人们担心其延长QT间隔的影响,但Ondansetron不会增加主要心脏不良事件 (MACE) 或成年人死亡的风险. 需要进一步的研究来优化药物安全警报.

科学领域:

药理学药理学是指药理学的学科.
心脏病学心脏病学
临床药房临床药房

背景情况:

昂丹塞特朗被标记为QT间隔延长,这是心脏事件的已知危险因素.
由于这种潜在的风险,药物安全警报中经常会引用ondansetron.
与QT延长相关的主要不良心脏事件 (MACE) 包括死亡,心脏骤停和心律失常.

研究的目的:

系统地审查和对丹塞特龙与MACE相关的文献进行元分析.
为了评估与QT延长相关的心脏事件的风险,与安慰剂相比,在接受Ondansetron的成年患者中.

主要方法:

搜索了Medline,Embase,国际制药摘要,以及Cochrane中央的相关随机对照试验 (RCT).
包括在成年人中比较Ondansetron与安慰剂的RCT,重点关注MACE结果.
进行随机效应的元分析,对零事件的研究进行校正.

主要成果:

包括170个RCT与23,421名成年参与者;70%是手术患者.
在所有包含的试验中,共有7例MACE (所有死亡) 报告.
丹塞与死亡风险增加 (RR:1.03,95% CI:0.76-1.39) 或心律失常无关.

结论:

目前的文献不支持使用丹塞和增加MACE或死亡率之间的关联.
由于报告心脏事件的数量很少,因此无法进行明确的元分析.
需要进一步的研究来完善对QT延长药物的理解,并优化药物安全警报.

更多相关视频

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Local Anesthetics: Adverse Effects

Local Anesthetics: Adverse Effects

While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...